Risk factors for pre-treatment mortality among HIV-infected children in rural Zambia: A cohort study

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Sutcliffe, Catherine G ^a   van Dijk, Janneke H ^b   Munsanje, Bornface ^b   Hamangaba, Francis ^b   Siniwymaanzi, Pamela ^b   Thuma, Philip E ^b   Moss, William J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b Macha Hospital   (Zambia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; AGE; ANEMIA; ARTICLE; BODY WEIGHT; BRAIN MALARIA; CHILD; CHILDHOOD MORTALITY; COHORT ANALYSIS; DIARRHEA; FEMALE; FOLLOW UP; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MEASLES; MENINGITIS; PNEUMONIA; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; RURAL AREA; SCHOOL CHILD; THERAPY DELAY; TUBERCULOSIS; ZAMBIA; MORTALITY; PRESCHOOL CHILD; RURAL POPULATION;

ANTI-HIV AGENTS; CHILD, PRESCHOOL; COHORT STUDIES; HIV INFECTIONS; HUMANS; RISK FACTORS; RURAL POPULATION; ZAMBIA;

EID: 83755229145     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029294     Document Type: Article

References (27)

1. WHO (2010) Towards Universal Access: Scaling up priority HIV/AIDS interventions in the health sector. Progress Report 2010 Geneva, Switzerland World Health Organization.
2. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ, (2008) Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 8: 477-489.
3. Sutcliffe CG, van Dijk JH, Bolton-Moore C, Cotham M, Tambatamba B, et al. (2010) Differences in presentation, treatment initiation and response among children infected with human immunodeficiency virus in urban and rural Zambia. Pediatr Infect Dis J 29: 849-854.
4. Carlucci JG, Kamanga A, Sheneberger R, Shepherd BE, Jenkins CA, et al. (2008) Predictors of adherence to antiretroviral therapy in rural Zambia. J Acquir Immune Defic Syndr 47: 615-622.
5. Bassett IV, Wang B, Chetty S, Mazibuko M, Bearnot B, et al. (2009) Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 51: 135-139.
6. Raguenaud M-E, Isaakidis P, Zachariah R, Te V, Soeung S, et al. (2009) Excellent outcomes among HIV+ children on ART, but unacceptably high pre-ART mortality and losses to follow-up: a cohort study from Cambodia. BMC Pediatr 9: 54.
7. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R, (2005) Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 19: 2141-2148.
8. Amuron B, Namara G, Birungi J, Nabiryo C, Levin J, et al. (2009) Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 9: 290.
9. Fairall LR, Bachmann MO, Louwagie GM, Van Vuuren C, Chikobvu P, et al. (2008) Effectiveness of Antiretroviral Treatment in a South African Program: a cohort study. Arch Intern Med 168: 86-93.
10. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, et al. (2006) Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 43: 770-776.
11. Togun T, Peterson I, Jaffar S, Oko F, Okomo U, et al. (2011) Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa. AIDS Res Ther 8: 24.
12. Marazzi MC, Germano P, Liotta G, Buonomo E, Guidotti G, et al. (2006) Pediatric highly active antiretroviral therapy in Mozambique: an integrated model of care. Minerva Pediatr 58: 483-490.
13. Charlebois ED, Ruel TD, Gasasira AF, Achan J, Kateera F, et al. (2010) Short-term risk of HIV disease progression and death in Ugandan children not eligible for antiretroviral therapy. J Acquir Immune Defic Syndr 55: 330-335.
14. van Dijk JH, Sutcliffe CG, Munsanje B, Hamangaba F, Thuma PE, et al. (2009) Barriers to the care of HIV-infected children in rural Zambia: a cross-sectional analysis. BMC Infect Dis 9: 169.
15. van Dijk JH, Sutcliffe CG, Munsanje B, Sinywimaanzi P, Hamangaba F, et al. (2011) HIV-infected children in rural Zambia achieve good immunologic and virologic outcomes two years after initiating antiretroviral therapy. PLoS One 6: e19006.
16. WHO (2006) Antiretroviral therapy of HIV infection in infants and children: Towards universal access. Recommendations for a public health approach Geneva, Switzerland World Health Organization.
17. WHO (2008) Report of the WHO Technical Reference Group, Paediatric HIV/ART Care Guideline Group Meeting Geneva, Switzerland World Health Organization.
18. The WHO child growth standards. Available at: http://www.who.int/childgrowth/en/index.html. Accessed August 2005.
19. WHO (2001) Iron deficiency anaemia: assessment, prevention and control. A guide for program managers Geneva, Switzerland World Health Organization.
20. DHS (2002) Demographic and Health Survey Zambia Final Report 2001/02.
21. Feucht UD, Kinzer M, Kruger M, (2007) Reasons for delay in initiation of antiretroviral therapy in a population of HIV-infected South African children. J Trop Pediatr 53: 398-402.
22. Walker AS, Mulenga V, Sinyinza F, Lishimpi K, Nunn A, et al. (2006) Determinants of survival without antiretroviral therapy after infancy in HIV-1-infected Zambian children in the CHAP Trial. J Acquir Immune Defic Syndr 42: 637-645.
23. Sutcliffe CG, Scott S, Mugala N, Ndhlovu Z, Monze M, et al. (2008) Survival from 9 months of age among HIV-infected and uninfected Zambian children prior to the availability of antiretroviral therapy. Clin Infect Dis 47: 837-844.
24. Cross Continents Collaboration for Kids (3Cs4kids) Analysis and Writing Committee (2008) Markers for predicting mortality in untreated HIV-infected children in resource-limited settings: a meta-analysis. AIDS 22: 97-105.
25. The KIDS-ART-LINC Collaboration (2008) Low risk of death, but substantial program attrition, in pediatric HIV treatment cohorts in Sub-Saharan Africa. J Acquir Immune Defic Syndr 49: 523-531.
26. Davies MA, Keiser O, Technau K, Eley B, Rabie H, et al. (2009) Outcomes of the South African National Antiretroviral Treatment Programme for children: the IeDEA Southern Africa collaboration. S Afr Med J 99: 730-737.
27. Bolton-Moore C, Mubiana-Mbewe M, Cantrell RA, Chintu N, Stringer EM, et al. (2007) Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia. Jama 298: 1888-1899.